If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.
Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL)
Intermediate or adverse cytogenetic risk
Acceptable hematologic and organ function
- AML associated with favorable risk karyotypes including inv(16), t(8;21), t(16;16), or t(15;17)
- Patients who are candidates for allogeneic stem cell transplant at the time of enrollment
- Patients with a history of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis
- Received prior treatment with HMA or chemotherapy for antecedent myelodysplastic syndrome (MDS